 Nicotinic Agonists
"Nicotinic Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and activate nicotinic cholinergic receptors (RECEPTORS, NICOTINIC). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission.
| Descriptor ID |
D018722
|
| MeSH Number(s) |
D27.505.519.625.120.140.700 D27.505.696.577.120.140.700
|
| Concept/Terms |
Nicotinic Agonists- Nicotinic Agonists
- Agonists, Nicotinic
- Cholinergic Agonists, Nicotinic
- Agonists, Nicotinic Cholinergic
- Nicotinic Cholinergic Agonists
- Nicotinic Agonist
- Agonist, Nicotinic
- Cholinergic Agonist, Nicotinic
- Agonist, Nicotinic Cholinergic
- Nicotinic Cholinergic Agonist
|
Below are MeSH descriptors whose meaning is more general than "Nicotinic Agonists".
Below are MeSH descriptors whose meaning is more specific than "Nicotinic Agonists".
This graph shows the total number of publications written about "Nicotinic Agonists" by people in this website by year, and whether "Nicotinic Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1999 | 2 | 0 | 2 | | 2000 | 3 | 2 | 5 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2004 | 2 | 2 | 4 | | 2005 | 1 | 0 | 1 | | 2006 | 2 | 2 | 4 | | 2007 | 2 | 3 | 5 | | 2008 | 3 | 0 | 3 | | 2009 | 5 | 0 | 5 | | 2010 | 2 | 0 | 2 | | 2011 | 3 | 1 | 4 | | 2012 | 6 | 1 | 7 | | 2013 | 3 | 1 | 4 | | 2014 | 5 | 0 | 5 | | 2015 | 4 | 2 | 6 | | 2016 | 1 | 1 | 2 | | 2017 | 6 | 3 | 9 | | 2019 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Nicotinic Agonists" by people in Profiles.
-
Rahman MM, Teng J, Worrell BT, Noviello CM, Lee M, Karlin A, Stowell MHB, Hibbs RE. Structure of the Native Muscle-type Nicotinic Receptor and Inhibition by Snake Venom Toxins. Neuron. 2020 06 17; 106(6):952-962.e5.
-
Tregellas JR, Wylie KP. Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia. Nicotine Tob Res. 2019 02 18; 21(3):349-356.
-
Lewis AS, Olincy A, Buchanan RW, Kem WR, Picciotto MR, Freedman R. Effects of a nicotinic agonist on the Brief Psychiatric Rating Scale five-factor subscale model in schizophrenia. Schizophr Res. 2018 05; 195:568-569.
-
Kress CM, Obi NU, Prochazka AV. In smokers with COPD, neither varenicline nor bupropion was linked to increased CV or neuropsychiatric risk vs NRT. Ann Intern Med. 2017 09 19; 167(6):JC31.
-
Littlewood RA, Claus ED, Wilcox CE, Mickey J, Arenella PB, Bryan AD, Hutchison KE. Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo. Psychopharmacology (Berl). 2017 Dec; 234(23-24):3417-3429.
-
Kem WR, Olincy A, Johnson L, Harris J, Wagner BD, Buchanan RW, Christians U, Freedman R. Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation. Neuropsychopharmacology. 2018 02; 43(3):583-589.
-
Wilcox CE, Calhoun VD, Rachakonda S, Claus ED, Littlewood RA, Mickey J, Arenella PB, Hutchison KE. Functional network connectivity predicts treatment outcome during treatment of nicotine use disorder. Psychiatry Res Neuroimaging. 2017 Jul 30; 265:45-53.
-
Smucny J, Tregellas JR. Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging. J Psychopharmacol. 2017 07; 31(7):801-811.
-
Veltri T, Taroyan N, Overton PG. Nicotine enhances an auditory Event-Related Potential component which is inversely related to habituation. J Psychopharmacol. 2017 07; 31(7):861-872.
-
Gee KW, Olincy A, Kanner R, Johnson L, Hogenkamp D, Harris J, Tran M, Edmonds SA, Sauer W, Yoshimura R, Johnstone T, Freedman R. First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288. J Psychopharmacol. 2017 04; 31(4):434-441.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|